Results 11 to 20 of about 49,428 (256)

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy

Pharmaceuticals, 2022
Although there have been extensive research and progress on the discovery of anticancer drug over the years, the application of these drugs as stand-alone therapy has been limited by their off-target toxicities, poor pharmacokinetic properties, and low ...
Audrey Nathania Johan, Yi Li
doaj   +1 more source

Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display

Microbial Cell Factories, 2018
Pioneered exactly 20 years ago, yeast surface display (YSD) continues to take a major role in protein engineering among the high-throughput display methodologies that have been developed to date. The classical yeast display technology relies on tethering
Doreen Könning, Harald Kolmar
doaj   +1 more source

Antibody–Drug Conjugates—A Tutorial Review

Molecules, 2021
Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small ...
Stephanie Baah, Mark Laws, Khondaker Miraz Rahman   +2 more
doaj   +1 more source

Resistance to Antibody–Drug Conjugates [PDF]

Cancer Research, 2018
Abstract Antibody–drug conjugates (ADC) are multicomponent molecules constituted by an antibody covalently linked to a potent cytotoxic agent. ADCs combine high target specificity provided by the antibody together with strong antitumoral properties provided by the attached cytotoxic agent.
García-Alonso, Sara, Ocaña, Alberto, Pandiella, Atanasio   +2 more
openaire   +3 more sources

Emerging new therapeutic antibody derivatives for cancer treatment

Signal Transduction and Targeted Therapy, 2022
Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin, Yanping Sun, Xiao Liang, Xinyu Gu, Jiangtao Ning, Yingchun Xu, Shuqing Chen, Liqiang Pan   +7 more
doaj   +1 more source

Antibody-drug conjugates for cancer therapy [PDF]

Farmacja Polska, 2021
Antibody – drug conjugates (ADCs) are drugs designed to target specific anti-cancer treatment. ADCs are immunoconjugates comprised of a monoclonal antibody attached to cytotoxic drug via a chemical linker.
Anna Grzywa
doaj   +1 more source

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs

Data in Brief, 2018
Experimental procedures and 1H and 13C NMR of the heterotrifunctional linker used for preparation of dual drug conjugates and PBD payload are included.
Amit Kumar, Krista Kinneer, Luke Masterson, Ebele Ezeadi, Philip Howard, Herren Wu, Changshou Gao, Nazzareno Dimasi   +7 more
doaj   +1 more source

Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer. [PDF]

PLoS ONE, 2016
Antibodies are widely available and cost-effective research tools in life science, and antibody conjugates are now extensively used for targeted therapy, immunohistochemical staining, or in vivo diagnostic imaging of cancer.
Steve Knutson, Erum Raja, Ryan Bomgarden, Marie Nlend, Aoshuang Chen, Ramaswamy Kalyanasundaram, Surbhi Desai   +6 more
doaj   +1 more source

Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation

Medicine in Drug Discovery, 2022
Antibody–drug conjugates (ADC) utilizing the targeting properties of antibodies and therapeutic effects of drugs have emerged a rapid development in recent years.
Weiran Cao, Rui Li, Xing Pei, Meihong Chai, Lu Sun, Yuanyu Huang, Jiancheng Wang, Stefan Barth, Fei Yu, Huining He   +9 more
doaj   +1 more source

An Immunosuppressive Antibody–Drug Conjugate [PDF]

Journal of the American Chemical Society, 2015
We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E, Liu, Tao, Wang, Ying, Cao, Yu, Du, Jintang, Luo, Xiaozhou, Deshmukh, Vishal, Kim, Chan Hyuk, Lawson, Brian R, Tremblay, Matthew S, Young, Travis S, Kazane, Stephanie A, Wang, Feng, Schultz, Peter G   +13 more
openaire   +4 more sources